RP
HAE icon

Riverwater Partners’s Haemonetics HAE Stock Holding History

Riverwater Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Buy
46,052
+15,041
+49% +$980K 0.87% 37
2025
Q4 		$2.49M Buy
31,011
+5,231
+20% +$351K 0.96% 27
2025
Q3 		$1.26M Sell
25,780
-19,143
-43% -$1.18M 0.52% 61
2025
Q2 		$3.35M Sell
44,923
-5,091
-10% -$337K 1.58% 9
2025
Q1 		$3.18M Sell
50,014
-365
-0.7% -$24.8K 1.63% 9
2024
Q4 		$3.93M Buy
50,379
+5,538
+12% +$445K 1.91% 8
2024
Q3 		$3.56M Buy
44,841
+29,109
+185% +$2.35M 1.77% 10
2024
Q2 		$1.3M Sell
15,732
-73
-0.5% -$6.42K 0.96% 23
2024
Q1 		$1.35M Buy
15,805
+21
+0.1% +$1.65K 0.99% 22
2023
Q4 		$1.35M Buy
15,784
+231
+1% +$20K 1.06% 17
2023
Q3 		$1.39M Sell
15,553
-162
-1% -$14.5K 1.27% 13
2023
Q2 		$1.34M Buy
15,715
+4,499
+40% +$380K 1.19% 16
2023
Q1 		$928K Buy
11,216
+2,098
+23% +$170K 0.85% 25
2022
Q4 		$717K Buy
+9,118
New +$733K 0.61% 48

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Riverwater Partners's HAE Position: Q1 2026 in Review

Riverwater Partners increased its Haemonetics (HAE) stake by 49% in Q1 2026, buying an estimated $980K and bringing the position to 46,052 shares worth $2.6M. The position accounts for 0.87% of the portfolio, ranked #37.

Riverwater Partners first reported a position in HAE in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.93M in Q4 2024. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Riverwater Partners held 46,052 shares of Haemonetics worth $2.6M as of Q1 2026.
  • Riverwater Partners bought 15,041 Haemonetics shares in Q1 2026, an estimated $980K.
  • Haemonetics made up 0.87% of Riverwater Partners's portfolio in Q1 2026, its #37 holding.
  • Riverwater Partners first reported a position in Haemonetics in Q4 2022 and has held it in 14 quarters since.
  • Riverwater Partners's Haemonetics position peaked at $3.93M in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Riverwater Partners's 13F filing for Q1 2026, filed 8 May 2026.